Previous studies have verified the anti-amyloid potential of SPT, which disrupts the amyloidation of insulin in vitro and in vivo [75,76], Alzheimer’s disease-related amyloid beta 42 [77], and biofilm-related bacterial amyloids [26,28]. Here, AGXT is linked to early-onset autosomal dominant Alzheimer disease.